Research progress on the application of liver transplantation in HIV combined with HCV positive patients

Yan Xijing; Yang Yang

doi:10.3969/j.issn.1674-7445.2020.06.005

Volume 11 Issue 6

Jan. 2021

Turn off MathJax

Article Contents

Article Navigation > ORGAN TRANSPLANTATION > 2020 > 11(6): 677-684

Yan Xijing, Yang Yang. Research progress on the application of liver transplantation in HIV combined with HCV positive patients[J]. ORGAN TRANSPLANTATION, 2020, 11(6): 677-684. doi: 10.3969/j.issn.1674-7445.2020.06.005

Citation:

PDF( 881 KB)

Research progress on the application of liver transplantation in HIV combined with HCV positive patients

doi: 10.3969/j.issn.1674-7445.2020.06.005

Yan Xijing,
Yang Yang^,

Department of Hepatic Surgery, Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China

More Information

Corresponding author: Yang Yang, Email:yysysu@163.com
Received Date: 2020-07-20
Available Online: 2021-01-19
Publish Date: 2021-01-19

Abstract

Abstract

With the advent of highly active antiretroviral therapy (HAART), acquired immune deficiency syndrome (AIDS) has gradually evolved from an incurable terminal disease to a controllable chronic disease. Due to the extended survival of AIDS patients, chronic renal failure and (or) chronic liver failure have become the main cause of death, and AIDS patients with chronic liver failure are constantly complicated with hepatitis C virus (HCV) infection. Human immunodeficiency virus (HIV) infection was previously considered as a contraindication for liver transplantation. With the deepening of medical cognition and improvement of surgical management experience, the quantity of HIV positive liver transplantation recipients has been steadily elevated and high long-term survival rate has been achieved. Nevertheless, the 3-, 5-, and 10-year survival rates after liver transplantation of HIV combined with HCV positive patients remain extremely low. In this article, the development of liver transplantation in HIV positive patients, the disease progression of HIV combined with HCV positive patients, and the treatment for the recurrence of viral hepatitis C after the operation were summarized.

FullText(HTML)

References(67)

References

[1]	MORABITO V, GROSSI P, LOMBARDINI L, et al. Solid organ transplantation in HIV⁺ recipients: Italian experience[J]. Transplant Proc, 2016, 48(2):424-430. DOI: 10.1016/j.transproceed.2015.12.049.
[2]	HIV in the United States and Dependent Areas[EB/OL].[2020-06-10]. https://www.cdc.gov/hiv/statistics/overview/ataglance.html.
[3]	LOCKE JE, DURAND C, REED RD, et al. Long-term outcomes after liver transplantation among human immunodeficiency virus-infected recipients[J]. Transplantation, 2016, 100(1):141-146. DOI: 10.1097/TP.0000000000000829.
[4]	BLUMBERG EA, STOCK P, AST Infectious Diseases Community of Practice. Solid organ transplantation in the HIV-infected patient[J]. Am J Transplant, 2009, 9 (Suppl 4):S131-S135. DOI: 10.1111/j.1600-6143.2009.02903.x.
[5]	STOCK PG, ROLAND ME. Evolving clinical strategies for transplantation in the HIV-positive recipient[J]. Transplantation, 2007, 84(5):563-571. DOI: 10.1097/01.tp.0000279190.96029.77.
[6]	LACOMBE K, ROCKSTROH J. HIV and viral hepatitis coinfections: advances and challenges[J]. Gut, 2012, 61(Suppl 1):i47-i58. DOI: 10.1136/gutjnl-2012-302062.
[7]	WEBER R, SABIN CA, FRⅡS-MØLLER N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study[J]. Arch Intern Med, 2006, 166(15):1632-1641. DOI: 10.1001/archinte.166.15.1632.
[8]	COOPER C, ROLLET-KURHAJEC KC, YOUNG J, et al. HIV virological rebounds but not blips predict liver fibrosis progression in antiretroviral-treated HIV/hepatitis C virus-coinfected patients[J]. HIV Med, 2015, 16(1):24-31. DOI: 10.1111/hiv.12168.
[9]	Joint United Nations Programme on HIV/AIDS (UNAIDS). Global HIV & AIDS statistics - 2020 fact sheet[EB/OL].[2020-05-05]. http://unaids.mio.guru/en/resources/fact-sheet.
[10]	WERBEL WA, DURAND CM. Solid organ transplantation in HIV-infected recipients: history, progress, and frontiers[J]. Curr HIV/AIDS Rep, 2019, 16(3):191-203. DOI: 10.1007/s11904-019-00440-x.
[11]	BACCARANI U, RIGHI E, ADANI GL, et al. Pros and cons of liver transplantation in human immunodeficiency virus infected recipients[J]. World J Gastroenterol, 2014, 20(18):5353-5362. DOI: 10.3748/wjg.v20.i18.5353.
[12]	MURILLAS J, RIMOLA A, LAGUNO M, et al. The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study[J]. Liver Transpl, 2009, 15(9):1133-1141. DOI: 10.1002/lt.21735.
[13]	VAN PILSUM RASMUSSEN SE, BOWRING MG, SHAFFER AA, et al. Knowledge, attitudes, and planned practice of HIV-positive to HIV-positive transplantation in US transplant centers[J]. Clin Transplant, 2018, 32(10):e13365. DOI: 10.1111/ctr.13365.
[14]	CAMPOS-VARELA I, DODGE JL, BERENGUER M, et al. Temporal trends and outcomes in liver transplantation for recipients with HIV infection in Europe and United States[J]. Transplantation, 2020, 104(10):2078-2086. DOI: 10.1097/TP.0000000000003107.
[15]	SORIANO V, PUOTI M, PETERS M, et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-hepatitis B virus international panel[J]. AIDS, 2008, 22(12):1399-1410. DOI: 10.1097/QAD.0b013e3282f8b46f.
[16]	SULKOWSKI MS. Management of hepatic complications in HIV-infected persons[J]. J Infect Dis, 2008, 197(Suppl 3):S279-S293. DOI: 10.1086/533414.
[17]	OCKENGA J, TILLMANN HL, TRAUTWEIN C, et al. Hepatitis B and C in HIV-infected patients. prevalence and prognostic value[J]. J Hepatol, 1997, 27(1):18-24. DOI: 10.1016/s0168-8278(97)80274-7.
[18]	STAPLES CT JR, RIMLAND D, DUDAS D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival[J]. Clin Infect Dis, 1999, 29(1):150-154. DOI: 10.1086/520144.
[19]	SORIANO V, GARCÍA-SAMANIEGO J, BRAVO R, et al. Morbidity and mortality associated with chronic viral hepatopathy in patients infected with the human immunodeficiency virus[J]. Med Clin (Barc), 1995, 104(17):641-644. http://www.ncbi.nlm.nih.gov/pubmed/7623489
[20]	BENHAMOU Y, BOCHET M, DI MARTINO V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. the multivirc group[J]. Hepatology, 1999, 30(4):1054-1058. DOI: 10.1002/hep.510300409.
[21]	PINEDA JA, ROMERO-GÓMEZ M, DÍAZ-GARCÍA F, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis[J]. Hepatology, 2005, 41(4):779-789. DOI: 10.1002/hep.20626.
[22]	PINEDA JA, GARCÍA-GARCÍA JA, AGUILAR-GUISADO M, et al. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy[J]. Hepatology, 2007, 46(3):622-630. DOI: 10.1002/hep.21757.
[23]	GARBA ML, PILCHER CD, BINGHAM AL, et al. HIV antigens can induce TGF-beta(1)-producing immunoregulatory CD8⁺ T cells[J]. J Immunol, 2002, 168(5):2247-2254. DOI: 10.4049/jimmunol.168.5.2247.
[24]	隋国德, 程广, 袁俊俊, 等. IL-13 PGE2 PGI2通过PKC通路活化肝星形细胞参与肝脏纤维化作用研究[J].现代医药卫生, 2017, 33(17):2591-2595. DOI: 10.3969/j.issn.1009-5519.2017.17.005. SUI GD, CHENG G, YUAN JJ, et al. Role of IL-13, PGE2 and PGI2 for participating in hepatic fibrosis by activating hepatic stellate cells through PKC path-way[J]. J Mod Med Health, 2017, 33(17):2591-2595. DOI: 10.3969/j.issn.1009-5519.2017.17.005.
[25]	王甘露, 邵圣文, 徐伯赢, 等.丙型肝炎病毒F蛋白上调肝星形细胞胶原表达[J].中国普外基础与临床杂志, 2010, 17(12):1258-1260. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgpwjcylczz201012009 WANG GL, SHAO SW, XU BY, et al. Up-regulation of collagen expression in hepatic stellate cells by F protein of hepatitis C virus[J]. Chin J Base Clin General Sur, 2010, 17(12):1258-1260. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgpwjcylczz201012009
[26]	SAFADI R, OHTA M, ALVAREZ CE, et al. Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes[J]. Gastroenterology, 2004, 127(3):870-882. DOI: 10.1053/j.gastro.2004.04.062.
[27]	王思奇.肝脏免疫微环境与肝纤维化的研究进展[J].复旦学报(医学版), 2018, 45(5):727-734. DOI: 10.3969/j.issn.1672-8467.2018.05.021. WANG SQ. Research progress in liver immune microenvironment and liver fibrosis[J]. Fudan Univ J Med Sci, 2018, 45(5):727-734. DOI: 10.3969/j.issn.1672-8467.2018.05.021.
[28]	WEN J, ZHOU Y, WANG J, et al. Interactions between Th1 cells and Tregs affect regulation of hepatic fibrosis in biliary atresia through the IFN-γ/STAT1 pathway[J]. Cell Death Differ, 2017, 24(6):997-1006. DOI: 10.1038/cdd.2017.31.
[29]	HSU YC, LIN JT, HO HJ, et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients[J]. Hepatology, 2014, 59(4):1293-1302. DOI: 10.1002/hep.26892.
[30]	CARVALHO RF, ATTA AM, DE OLIVEIRA IS, et al. Adiponectin levels and insulin resistance among patients with chronic hepatitis C[J]. Acta Trop, 2018, 178:258-263. DOI: 10.1016/j.actatropica.2017.12.004.
[31]	BLANCO F, BARREIRO P, RYAN P, et al. Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance[J].J Viral Hepat, 2011, 18(1):11-16. DOI: 10.1111/j.1365-2893.2009.01261.x.
[32]	GANESAN M, POLUEKTOVA LY, KHARBANDA KK, et al. Liver as a target of human immunodeficiency virus infection[J]. World J Gastroenterol, 2018, 24(42):4728-4737. DOI: 10.3748/wjg.v24.i42.4728.
[33]	MORENO A, CERVERA C, FORTÚN J, et al. Epidemiology and outcome of infections in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients: a FIPSE/GESIDA prospective cohort study[J]. Liver Transpl, 2012, 18(1):70-81. DOI: 10.1002/lt.22431.
[34]	HONG F, SAIMAN Y, SI C, et al. X4 human immunodeficiency virus type 1 gp120 promotes human hepatic stellate cell activation and collagen I expression through interactions with CXCR4[J]. PLoS One, 2012, 7(3):e33659. DOI: 10.1371/journal.pone.0033659.
[35]	DAGUR RS, WANG W, CHENG Y, et al. Human hepatocyte depletion in the presence of HIV-1 infection in dual reconstituted humanized mice[J]. Biol Open, 2018, 7(2):bio029785. DOI: 10.1242/bio.029785.
[36]	MUNSHI N, BALASUBRAMANIAN A, KOZIEL M, et al. Hepatitis C and human immunodeficiency virus envelope proteins cooperatively induce hepatocytic apoptosis via an innocent bystander mechanism[J]. J Infect Dis, 2003, 188(8):1192-1204. DOI: 10.1086/378643.
[37]	JANG JY, SHAO RX, LIN W, et al. HIV infection increases HCV-induced hepatocyte apoptosis[J]. J Hepatol, 2011, 54(4):612-620. DOI: 10.1016/j.jhep.2010.07.042.
[38]	BRUNO R, GALASTRI S, SACCHI P, et al. gp120 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis[J]. Gut, 2010, 59(4):513-520. DOI: 10.1136/gut.2008.163287.
[39]	VALI B, YUE FY, JONES RB, et al. HIV-specific T-cells accumulate in the liver in HCV/HIV co-infection[J]. PLoS One, 2008, 3(10):e3454. DOI: 10.1371/journal.pone.0003454.
[40]	SANDLER NG, DOUEK DC. Microbial translocation in HIV infection: causes, consequences and treatment opportunities[J]. Nat Rev Microbiol, 2012, 10(9):655-666. DOI: 10.1038/nrmicro2848.
[41]	GE D, FELLAY J, THOMPSON AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance[J]. Nature, 2009, 461(7262):399-401. DOI: 10.1038/nature08309.
[42]	RALLÓN NI, NAGGIE S, BENITO JM, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients[J]. AIDS, 2010, 24(8):F23-F29. DOI: 10.1097/QAD.0b013e3283391d6d.
[43]	MANZARDO C, LONDOÑO MC, CASTELLS L, et al. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: a prospective nationwide cohort study[J]. Am J Transplant, 2018, 18(10):2513-2522. DOI: 10.1111/ajt.14996.
[44]	TANAKA T, AKAMATSU N, KANEKO J, et al. Daclatasvir and asunaprevir for recurrent hepatitis C following living donor liver transplantation with HIV co-infection[J]. Hepatol Res, 2016, 46(8):829-832. DOI: 10.1111/hepr.12614.
[45]	DUCLOS-VALLÉE JC, FÉRAY C, SEBAGH M, et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus[J]. Hepatology, 2008, 47(2):407-417. DOI: 10.1002/hep.21990.
[46]	MIRO JM, MONTEJO M, CASTELLS L, et al. Outcome of HCV/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study[J]. Am J Transplant, 2012, 12(7):1866-1876. DOI: 10.1111/j.1600-6143.2012.04028.x.
[47]	TERRAULT NA, ROLAND ME, SCHIANO T, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection[J]. Liver Transpl, 2012, 18(6):716-726. DOI: 10.1002/lt.23411.
[48]	MIRO JM, STOCK P, TEICHER E, et al. Outcome and management of HCV/HIV coinfection pre- and post-liver transplantation. a 2015 update[J]. J Hepatol, 2015, 62(3):701-711. DOI: 10.1016/j.jhep.2014.10.032.
[49]	KAMATH PS, WIESNER RH, MALINCHOC M, et al. A model to predict survival in patients with end-stage liver disease[J]. Hepatology, 2001, 33(2):464-470. DOI: 10.1053/jhep.2001.22172.
[50]	SULKOWSKI MS. Viral hepatitis and HIV coinfection[J]. J Hepatol, 2008, 48(2):353-367. DOI: 10.1016/j.jhep.2007.11.009.
[51]	FERRARESE A, ZANETTO A, GAMBATO M, et al. Liver transplantation for viral hepatitis in 2015[J]. World J Gastroenterol, 2016, 22(4):1570-1581. DOI: 10.3748/wjg.v22.i4.1570.
[52]	TE HS. Recurrent hepatitis C: the bane of transplant hepatology[J]. Hepatology, 2014, 59(1):21-23. DOI: 10.1002/hep.26591.
[53]	BERENGUER M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin[J]. J Hepatol, 2008, 49(2):274-287. DOI: 10.1016/j.jhep.2008.05.002.
[54]	DUCLOS-VALLEE JC, TATEO M, TEICHER E, et al. Results of liver transplantation in a large cohort of more than 100 HIV infected patients - a monocentric experience[J]. Hepatology, 2011, 54(suppl 4):361A. http://www.researchgate.net/publication/295927763_Results_of_Liver_Transplantation_in_a_Large_Cohort_of_More_Than_100_HIV_Infected_Patients_-_A_Monocentric_Experience
[55]	TERRAULT N, REDDY KR, POORDAD F, et al. Peginterferon and ribavirin for treatment of recurrent hepatitis C disease in HCV-HIV coinfected liver transplant recipients[J]. Am J Transplant, 2014, 14(5):1129-1135. DOI: 10.1111/ajt.12668.
[56]	CASTELLS L, RIMOLA A, MANZARDO C, et al. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study[J]. J Hepatol, 2015, 62(1):92-100. DOI: 10.1016/j.jhep.2014.07.034.
[57]	PELLICELLI AM, MONTALBANO M, LIONETTI R, et al. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late[J]. Dig Liver Dis, 2014, 46(10):923-927. DOI: 10.1016/j.dld.2014.06.004.
[58]	ANTONINI TM, FURLAN V, TEICHER E, et al. Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation[J]. AIDS, 2015, 29(1):53-58. DOI: 10.1097/QAD.0000000000000516.
[59]	李俊利, 尚佳, 宁会彬.直接抗病毒药物时代特殊人群HCV感染的管理和治疗[J].临床肝胆病杂志, 2018, 34(2):242-245. DOI: 10.3969/j.issn.1001-5256.2018.02.005. LI JL, SHANG J, NING HB. Management and treatment of special populations with hepatitis C virus infection in the era of direct-acting antiviral agents[J]. J Clin Hepatol, 2018, 34(2):242-245. DOI: 10.3969/j.issn.1001-5256.2018.02.005.
[60]	European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018[J]. J Hepatol, 2018, 69(2):461-511. DOI: 10.1016/j.jhep.2018.03.026.
[61]	HOUSSEL-DEBRY P, COILLY A, FOUGEROU-LEURENT C, et al. 12 weeks of a ribavirin-free sofosbuvir and nonstructural protein 5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation[J]. Hepatology, 2018, 68(4):1277-1287. DOI: 10.1002/hep.29918.
[62]	SALCEDO M, PRIETO M, CASTELLS L, et al. Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. role of cirrhosis and genotype 3. a multicenter cohort study[J]. Transpl Int, 2017, 30(10):1041-1050. DOI: 10.1111/tri.12999.
[63]	REAU N, KWO PY, RHEE S, et al. Glecaprevir/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection[J]. Hepatology, 2018, 68(4):1298-1307. DOI: 10.1002/hep.30046.
[64]	CHEN JY, FEENEY ER, CHUNG RT. HCV and HIV co-infection: mechanisms and management[J]. Nat Rev Gastroenterol Hepatol, 2014, 11(6):362-371. DOI: 10.1038/nrgastro.2014.17.
[65]	BULTEEL N, LEEN C. Editorial: direct-acting anti-virals-not the be-all and end-all in HIV/HCV co-infection[J]. Aliment Pharmacol Ther, 2017, 45(4):569-570. DOI: 10.1111/apt.13884.
[66]	SCHLABE S, ROCKSTROH JK. Advances in the treatment of HIV/HCV coinfection in adults[J]. Expert Opin Pharmacother, 2018, 19(1):49-64. DOI: 10.1080/14656566.2017.1419185.
[67]	李雯彬, 张文杰, 张晓瑛, 等.直接抗病毒药物时代下丙型病毒性肝炎的研究现状[J].中国中西医结合消化杂志, 2018, 26(10):886-891. DOI: 10.3969/j.issn.1671-038X.2018.10.19. LI WB, ZHANG WJ, ZHANG XY, et al. Research status of hepatitis C virus in the era of liver direct antiviral drugs[J]. Chin J Integr Trad West Med Dig, 2018, 26(10):886-891. DOI: 10.3969/j.issn.1671-038X. 2018.10.19.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (141) PDF downloads(18)

Research progress on the application of liver transplantation in HIV combined with HCV positive patients

doi: 10.3969/j.issn.1674-7445.2020.06.005

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Research progress on the application of liver transplantation in HIV combined with HCV positive patients

doi: 10.3969/j.issn.1674-7445.2020.06.005

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Export File

Citation

Format

Content